Some patients need dose adjustments, side effect management, protein support, strength training guidance, or a broader evaluation of hormonal and metabolic factors
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes Published March 29, 2025 N Engl J Med 2025;392:2001-2012 DOI: 10.1056/NEJMoa2501006 Abstract Background The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk
F.EL-MaraghyN
GLP-1 receptor agonists are generally considered safe and effective when prescribed appropriately
Be sure to reduce fructose and oxalate levels during this period of time
Safety and administration Users have reported improved sleep, skin health, and rapid muscle recovery